StockData
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. (ANIK) stock

ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/30
$13.23−0.05 (-0.38%)

Close on Nov 20, 2026Market cap $177.06MP/E –Yield –

Anika Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Anika Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $562.00K. For fiscal 2025 it was $4.36M. Over ten years it grew -17.7% a year on average. The highest annual figure on record is $38.43M in fiscal 2014.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.36M–
FY2024Dec 31, 2024-$2.33M–
FY2023Dec 31, 2023-$7.22M–
FY2022Dec 31, 2022-$3.08M-194.6%
FY2021Dec 31, 2021$3.25M-71.5%
FY2020Dec 31, 2020$11.44M-66.5%
FY2019Dec 31, 2019$34.18M+12.9%
FY2018Dec 31, 2018$30.26M-4.9%
FY2017Dec 31, 2017$31.83M+205.1%
FY2016Dec 31, 2016$10.43M-66.0%
FY2015Dec 31, 2015$30.69M-20.1%
FY2014Dec 31, 2014$38.43M+55.4%
FY2013Dec 31, 2013$24.72M+173.4%
FY2012Dec 31, 2012$9.04M+3.1%
FY2011Dec 31, 2011$8.77M+73.1%
FY2010Dec 31, 2010$5.07M–
FY2009Dec 31, 2009-$867.53K–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.13M–
Q1 FY2026Mar 31, 2026-$6.28M–
Q4 FY2025Dec 31, 2025$3.99M+1350.5%
Q3 FY2025Sep 30, 2025$4.98M+31.1%
Q2 FY2025Jun 30, 2025-$1.66M–
Q1 FY2025Mar 31, 2025-$2.95M–
Q4 FY2024Dec 31, 2024$275.00K-84.7%
Q3 FY2024Sep 30, 2024$3.80M-33.8%
Q2 FY2024Jun 30, 2024-$4.47M–
Q1 FY2024Mar 31, 2024-$1.93M–
Q4 FY2023Dec 31, 2023$1.80M–
Q3 FY2023Sep 30, 2023$5.74M+464.2%
Q2 FY2023Jun 30, 2023-$9.75M-949.3%
Q1 FY2023Mar 31, 2023-$5.01M–
Q4 FY2022Dec 31, 2022-$2.05M-161.2%
Q3 FY2022Sep 30, 2022$1.02M+30.8%
Q2 FY2022Jun 30, 2022$1.15M-42.0%
Q1 FY2022Mar 31, 2022-$3.20M–
Q4 FY2021Dec 31, 2021$3.35M+56.5%
Q3 FY2021Sep 30, 2021$778.00K-86.1%
Q2 FY2021Jun 30, 2021$1.98M-41.5%
Q1 FY2021Mar 31, 2021-$2.85M-984.5%
Q4 FY2020Dec 31, 2020$2.14M-83.2%
Q3 FY2020Sep 30, 2020$5.59M-41.9%
Q2 FY2020Jun 30, 2020$3.38M-22.6%
Q1 FY2020Mar 31, 2020$322.00K-95.7%
Q4 FY2019Dec 31, 2019$12.75M+29.5%
Q3 FY2019Sep 30, 2019$9.62M-0.1%
Q2 FY2019Jun 30, 2019$4.37M+17.1%
Q1 FY2019Mar 31, 2019$7.43M+5.4%
Q4 FY2018Dec 31, 2018$9.85M+118.5%
Q3 FY2018Sep 30, 2018$9.63M+1.3%
Q2 FY2018Jun 30, 2018$3.73M-7.4%
Q1 FY2018Mar 31, 2018$7.05M-48.9%
Q4 FY2017Dec 31, 2017$4.51M-3.4%
Q3 FY2017Sep 30, 2017$9.51M+10.9%
Q2 FY2017Jun 30, 2017$4.03M–
Q1 FY2017Mar 31, 2017$13.79M–
Q4 FY2016Dec 31, 2016$4.66M–
Q3 FY2016Sep 30, 2016$8.58M–

More Anika Therapeutics figures

See a number that looks wrong?